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Summary
The risk of osteoporosis increases in inflammatory disorders. In cell-
mediated immune activation, interferon (IFN)-γ stimulates macrophage
release of neopterin and increases the activity of indoleamine 2,3-
dioxygenase (IDO), thereby stimulating tryptophan degradation along the
kynurenine pathway. Plasma levels of neopterin and the kynurenine/
tryptophan ratio (KTR) are thus markers of IFN-γ-mediated inflammation.
Several kynurenine pathway metabolites (kynurenines) possess
immunomodulatory properties. The aim of this study was to investigate
associations between markers of IFN-γ-mediated inflammation and
kynurenines with bone mineral density (BMD). The community-based
Hordaland Health Study (HUSK), with middle-aged (46–49 years) and older
(71–74 years) participants, was conducted from 1998 to 2000 (n = 5312). Hip
BMD in relation to neopterin, KTR and kynurenines were investigated, using
linear and logistic regression analyses. In the oldest group, neopterin
(P ≤ 0·019) and KTR (P ≤ 0·001) were associated inversely with BMD after
multiple adjustment. Comparing the highest to the lowest quartiles, the odds
ratios of low BMD (being in the lowest quintile of BMD) in the oldest cohort
were for neopterin 2·01 among men and 2·34 among women (P ≤ 0·007) and
for KTR 1·80 for men and 2·04 for women (P ≤ 0·022). Xanthurenic acid was
associated positively with BMD in all sex and age groups while
3-hydroxyanthranilic acid was associated positively with BMD among
women only (P ≤ 0·010). In conclusion, we found an inverse association
between BMD and markers of IFN-γ-mediated inflammation in the oldest
participants. BMD was also associated with two kynurenines in both age
groups. These results may support a role of cell-mediated inflammation in
bone metabolism.
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Introduction
Patients with chronic inflammatory diseases are at increased
risk of secondary osteoporosis, a result of unbalanced bone
turnover with increased maturation and activation of bone-
degrading cells (osteoclasts) [1,2]. The main common
pathway of osteoclast stimulation is through increased
release of receptor activator of nuclear factor kappa B (NF-
κB) ligand (RANKL) [2] by cells embedded in bone matrix
(osteocytes), bone-building cells (osteoblasts) and stromal
cells [3]. Experimental studies have indicated that in states
of inflammation, RANKL is also secreted by activated T
cells [4,5].
C-reactive protein (CRP) increases as an acute-phase
response to inflammation or tissue damage [6]. Low-grade
chronic inflammation may be assessed by high-sensitivity
(hs) CRP. Results from studies on CRP in relation to bone
mineral density (BMD) have been conflicting [7–11].
In certain conditions, including infections, inflammatory
diseases and oestrogen deficiency, release of interferon
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(IFN)-γ is stimulated as part of a cell-mediated (type 1)
immune response [12–14]. IFN-γ has a mainly bone protec-
tive effect [15], e.g. through down-regulation of osteoclast
maturation (bone-degrading cells). However, in inflamma-
tory conditions with excess IFN-γ release, murine studies
have indicated that a bone resorptive effect dominates [5].
IFN-γ stimulates macrophage release of neopterin, a
pteridine serving as a marker of cellular immune activation
[16]. IFN-γ also increases the expression of the enzyme
indoleamine 2,3 dioxygenase (IDO) [17], catalyzing the oxi-
dative cleavage of tryptophan to kynurenine, which is
further metabolized to compounds collectively termed
kynurenines (Fig. 1) [18]. The kynurenine/tryptophan ratio
(KTR) is a sensitive marker of IDO activity and immune
activation [18,19].
IDO is an immunomodulatory enzyme [20,21] which
may, as for the kynurenines, have an impact upon T cell
activity. This influence may be through modification of the
properties of antigen-presenting cells [22] and induction of
regulatory T cells (Tregs) [23], inhibition of T cell prolifera-
tion [24] or through tryptophan depletion, creating a
microenvironment suppressing T cell activity [25]. In some
diseases, suppression of Tregs has been suggested as a mecha-
nism for bone loss [26–28].
Activation of the kynurenine pathway, as well as an
increase in serum neopterin, has been linked to several
chronic conditions, including rheumatic diseases [29–32],
cardiovascular disease [33], mental and neurological illness
[34,35] and osteoporosis [36].
Little is known about the relation between neopterin, the
kynurenine pathway and BMD. Thus, the aim of this study
was to investigate whether neopterin, KTR and metabolites
of the kynurenine pathway are associated with BMD in a
large community-based sample of middle-aged and older
adults.
Materials and methods
Subjects
The bone mineral substudy of the Hordaland Health Study
(HUSK) was conducted during 1998–2000. Some 9187
inhabitants of Bergen and three neighbouring suburban
municipalities, born in 1925–27 and 1950–51, who had par-
ticipated previously in the Hordaland Homocysteine Study
[37], were invited. The 7074 (77·0% of invited) subjects
taking part in HUSK answered questions concerning life-
style factors, health status and medication use. BMD was
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Fig. 1. The kynurenine pathway of tryptophan
metabolism. Tryptophan is an essential amino
acid obtained through the diet. Tryptophan
metabolism is initiated by cleavage of the
indole-ring catalyzed by either tryptophan
dioxygenase (TDO) or indoleamine
2,3-dioxygenase (IDO). TDO resides primarily
in the liver and is induced by tryptophan and
corticosteroids, whereas IDO is an extrahepatic
enzyme induced by cytokines, mainly interferon
(IFN)-γ, as indicated by the attached filled
circle. Other enzymes of the kynurenine
pathway are probably also induced by cytokines,
as indicated by the attached open circles. AMO:
anthranilate monooxygenase; HAO:
hydroxyanthranilate dioxygenase; KAT:
kynurenine aminotransferase; KMO:
kynurenine monooxygenase; KYNU:
kynureninase; QRPT: quinolinate
phosphoribosyl transferase.
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measured in 5408 participants (76·4% of participating sub-
jects); 33 scans were invalid or rejected because of bilateral
hip prostheses, leaving 5375 valid bone scans. Of these,
blood samples were available for 5314 subjects, leaving
75·1% of participants eligible for the study. The study pro-
tocol was approved by the Regional Committee for Medical
Research Ethics and the Norwegian Data Inspectorate. All
participants signed an informed consent. The study was
conducted according to the principles of the Declaration of
Helsinki of the World Medical Association.
Blood samples
Non-fasting blood samples were collected and stored as
described earlier [38]. Plasma was analysed for tryptophan,
kynurenines (kynurenine, kynurenic acid, anthranilic
acid, 3-hydroxykynurenine, xanthurenic acid and
3-hydroxyanthranilic acid), neopterin and cotinine (a nico-
tine metabolite used as a biomarker of recent nicotine
exposure) using liquid chromatography-tandem mass spec-
trometry (LC/MS/MS) in the laboratory of Bevital A/S
(http://www.bevital.no), Bergen, Norway [39]. Before analy-
ses, the blood samples had been stored for up to 13 years at
−80°C. Plasma concentrations of some kynurenines, which
may change in samples that have not been properly stored,
were similar in our analyses to those obtained in fresh
samples [40], indicating that sample collection and storage
were adequate.
Sensitive C-reactive protein ethylenediamine tetraacetic
acid (EDTA) plasma levels were analysed at Bevital A/S by
an immunoassay based on matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry (MALDI-TOF
MS).
Bone mineral density
Bone mineral density was measured during 1998–2000
using a stationary, dual X-ray densitometer (EXPERT-XL,
software versions 1·72 and 1·90; Lunar Company Inc.,
Madison, WI, USA).
A scan of the left hip was used, except in those with a left
hip prosthesis or former hip fracture. The right hip was
scanned in 3·8% of subjects. The scanner was calibrated
daily against a standard calibration block. The coefficient of
variation for total hip BMD measurements based on dupli-
cate measurement in 27 individuals was 1·2% [41]. Daily
phantom measurements were performed and showed no
drift. Several areas of the hip were measured; in this study
we report the findings for total hip BMD.
Additional data
Participants provided information on health status, use of
medication, socio-demographic data and lifestyle factors by
self-administered questionnaires. Height and weight were
measured in light clothing and body mass index (BMI; in
kg/m2) was calculated.
Statistical analyses
Distribution of continuous variables is reported as means
and standard deviations (s.d.) or medians and interquartile
range for skewed distributions. For categorical variables,
counts (percentages) are reported. BMD, BMI and trypto-
phan were normally distributed, as determined by Q-Q
plot. CRP, neopterin, KTR, the kynurenines and cotinine
displayed right-skewed distributions. Cotinine was catego-
rized to show the proportions of participants with no, light
or heavy nicotine exposure, but was used as a continuous
variable in all the analyses. Potential differences between sex
and age groups were compared using two-way analysis of
variance for continuous outcome variables and binary
logistic regression for the categorical outcome.
Correlations between inflammatory markers/tryptophan
metabolites and BMD were assessed by Spearman’s rho (rs)
for the four sex and age groups. The relationships between
BMD and neopterin, KTR and the kynurenines were further
examined using multiple linear regression. Further, BMD
was dichotomized into low (lowest 20% in each sex and age
group) or normal BMD. Odds ratios (OR) for risk of low
BMD were estimated across sex- and age-specific quartiles
of neopterin, KTR, tryptophan and kynurenines by binary
logistic regression. The multivariable model includes BMI,
cotinine and estimated glomerular filtration rate (eGFR)
calculated by the Modification of Diet in Renal Disease
(MDRD) formula [42]. eGFR was dichotomized according
to normal (60 ml/min or above) or reduced (below 60 ml/
min) renal function.
The significance level was set to 0·05. Analyses were con-
ducted using the statistical packages r (version 2·13·1 for
Windows) and spss (version 18 for Windows; SPSS Inc.,
Chicago, IL, USA).
Results
Characteristics of the study participants, according to sex
and age group, are shown in Table 1. The plasma neopterin
concentration was higher in women than men, whereas
KTR was similar between the sexes within each age group.
For tryptophan and most of the kynurenines, median values
were higher among men than women. The exception was
3-hydroxykynurenine, which was higher among women
than men in the middle-aged group. In both age groups,
reduced eGFR was substantially more prevalent in women
than men.
The association between neopterin and KTR for both age
groups combined was stronger (rs = 0·55, P < 0·001) than
the associations between neopterin and CRP (rs = 0·23,
P < 0·001) and KTR and CRP (rs = 0·27, P < 0·001). Spear-
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man’s correlation coefficients of CRP, neopterin, KTR, tryp-
tophan and the kynurenines with BMD and the covariables
BMI, cotinine and eGFR are shown in Table 2. BMD was
associated inversely with neopterin and KTR (KTR only in
men) in the oldest age group. For kynurenic acid,
xanthurenic acid and 3-hydroxyanthranilic acid, positive
associations with BMD were found in all age and sex groups
(P < 0·001). Additionally, KTR, kynurenine, kynurenic acid,
3-hydroxykynurenine and 3-hydroxyanthranilic acid, but
not neopterin, were correlated significantly with BMI in all
age and sex groups.
In multiple adjusted linear regression analyses, BMD was
associated negatively with CRP only in the oldest men
(Table 3). Further, BMD was associated negatively with
neopterin and KTR in the oldest, but not in the middle-
aged group. Among the kynurenines, positive associations
with BMD were found for xanthurenic acid (all sex and age
groups) and 3-hydroxyanthtranilic acid (women only).
The risk of having low BMD (being in the lowest quintile
of BMD) was assessed by logistic regression analyses
(Table 4). In the oldest, a higher OR for low BMD was
found in the highest, compared to the lowest, quartiles of
CRP (only men), neopterin and KTR. The OR for low BMD
was decreased significantly in the highest compared to the
lowest quartiles of tryptophan, xanthurenic acid and
3-hydroxyanthranilic acid among both older men and
women, and increased for the highest quartile of
3-hydroxykynurenine in older women. Corresponding
analyses in the age group 46–49 years yielded no significant
trends or associations (data not shown).
Discussion
In this study, we have investigated BMD in relation to two
markers of IFN-γ-mediated inflammation, neopterin and
KTR, as well as the relation between BMD and metabolites
of the kynurenine pathway. BMD was associated inversely
with neopterin and KTR in the older (71–74 years) but
not the middle-aged (46–49 years) groups. BMD showed a
positive association with xanthurenic acid in all age–sex
groups and with 3-hydroxyanthranilic acid among women
in both age groups. Further, the proportion of older
men and women with low BMD was significantly smaller
in the lowest compared to the highest quartile of
3-hydroxyanthranilic acid.
The strengths of this study include the large number of
participants of both genders, and the comprehensive labo-
ratory analyses quantifying neopterin as well as all
kynurenines along the pathway from tryptophan to
3-hydroxyanthranilic acid by a single analytical method for
each subject. A limitation includes the cross-sectional
design, which does not preclude reverse causation. In this
study plasma metabolites were measured only at a single
time-point, which does not necessarily reflect possible long-
term changes during the progression of osteoporosis [43].
Table 1. Characteristics of participants in the Hordaland Health Study (n = 5312) according to age and sex.
46–49 years 71–74 years P-values
Men
n = 1229*
Women
n = 1862*
Men
n = 1017*
Women
n = 1204* Sex Age
Sex × age
interaction
BMD total hip (g/cm2), mean (s.d.)† 1·03 (0·14) 0·98 (0·13) 0·96 (0·15) 0·80 (0·13) <0·001
BMI (kg/ m2), mean (s.d.)† 26·2 (3·3) 24·8 (4·0) 26·0 (3·1) 26·2 (4·2) <0·001
eGFR below 60 ml/min, n (%)‡ 12 (1·0) 294 (15·8) 194 (19·1) 652 (54·2) <0·001
Cotinine, n (%)† 0·001 <0·001 n.s.
<85 (no nicotine exposure) 784 (63·8) 1180 (63·4) 834 (82·0) 1016 (84·4)
85–1000 (light nicotine exposure) 139 (11·3) 258 (13·9) 60 (5·9) 97 (8·1)
>1000 (heavy nicotine exposure) 306 (24·9) 424 (22·8) 123 (12·1) 91 (7·6)
Inflammatory markers, median (IQR)
CRP (μg/ml)† 1·2 (2·1) 1·0 (2·1) 2·1 (3·2) 2·1 (3·2) 0·030 <0·001 n.s.
Neopterin (nmol/l)† 6·6 (2·2) 7·0 (2·3) 8·6 (3·3) 8·7 (3·2) 0·004
KTR (×1000)† 20·1 (6·3) 20·0 (6·8) 25·8 (9·9) 26·2 (9·7) n.s. <0·001 n.s.
Metabolites, median (IQR)
Tryptophan (μmol/l)† 72·3 (18·8) 65·7 (17·2) 68·5 (17·8) 62·5 (17·5) <0·001 <0·001 n.s.
Kynurenine (μmol/Ll)† 1·5 (0·4) 1·3 (0·4) 1·8 (0·6) 1·7 (0·6) <0·001 <0·001 n.s.
Kynurenic acid (nmol/l)† 45·1 (18·4) 39·2 (17·5) 54·7 (26·9) 48·4 (25·6) <0·001 <0·001 n.s.
Anthranilic acid (nmol/l)† 13·0 (5·0) 12·7 (5·3) 17·0 (7·9) 15·9 (6·6) 0·004 <0·001 n.s.
3-Hydroxykynurenine (nmol/l)† 28·5 (11·8) 30·2 (13·2) 36·1 (15·1) 35·3 (15·3) <0·001
Xanthurenic acid (nmol/l)† 17·2 (10·2) 15·4 (9·8) 17·0 (11·1) 14·2 (9·1) 0·001
3-Hydroxyanthranilic acid (nmol/l)† 34·8 (17·3) 30·9 (15·1) 36·7 (19·0) 32·9 (17·1) <0·001 <0·001 n.s.
*Total numbers may vary between variables according to different numbers of missing data. †Groups compared by two-way analysis of variance.
‡Groups compared by binary logistic regression. BMD = bone mineral density; BMI = body mass index; eGFR = estimated glomerular filtration rate;
IQR = interquartile range; KTR = kynurenine/tryptophan ratio; n.s. = not significant; P > 0·01; s.d. = standard deviation.
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The inflammatory markers neopterin and KTR have been
reported previously to be associated positively with age-
related diseases [33,44]. KTR is also associated directly with
BMI [45,46] and smoking [47], and inversely with renal
function [46,48]. These three factors are strong predictors
of BMD [49] and were therefore adjusted for as potential
confounders in the analyses. Concentrations of neopterin,
tryptophan and kynurenine were comparable to levels
found in other studies [33,50]. 3-Hydroxykynurenine and
3-hydroxyanthranilic acid are labile compounds, but con-
centrations in the present study were comparable to previ-
ously published levels from analyses in fresh blood [40].
Tumour necrosis factor (TNF), interleukin (IL)-1 and
IL-6 are major stimulators of CRP release. These inflamma-
tory cytokines may mediate bone loss directly by stimulat-
ing osteoclast formation and maturation or indirectly by
promoting RANKL release, thereby increasing osteoclast
activity [15,51]. In the present study a negative association
between CRP and BMD was found only among elderly
men. Among elderly women we found an association of
BMD in total hip with CRP in bivariate, but not in multiple
adjusted analyses, which is in concordance with one other
study [11]. Previously, an inverse association between BMD
and CRP has been found in some [7,8] but not all studies
[9,10].
IFN-γ is the principal inducer of neopterin production
and the kynurenine pathway, and is produced locally in
bone tissue by cells of immune origin and mesenchymal
stem cells [52]. IFN-γ is an inhibitor of osteoclast forma-
tion and bone resorption [52], but may exhibit a dual effect
on bone [15]. In a mouse model mimicking inflammation,
infection and oestrogen deficiency, i.e. various conditions
predisposing to bone loss, the net effect of IFN-γ was pro-
resorptive [5]. This finding is in concordance with our
study, where the inflammatory markers neopterin and KTR
were associated inversely with BMD among the oldest par-
ticipants. This inverse association was most evident in
elderly patients with low BMD, and strongest among older
women. IFN-γ signalling as a target for treatment of osteo-
porosis has been proposed [5,53]. In contrast, in a study
comparing cytokine gene expression in bone tissue from
osteoporotic versus osteoarthritic patients, a higher expres-
sion of IFN-γ-related genes in osteoarthritic hip specimens
was found, indicating an anti-osteoclastogenic activity of
IFN-γ [54]. Although this study is not directly comparable
with the present study, the conflicting results may indicate
a difference in local versus systemic impact of IFN-γ
activity.
Besides being a marker of IFN-γ activity, elevated
neopterin also reflects increased production of reactive
oxygen species [55], and its concentration in serum is corre-
lated with the clinical course of infections with viruses,
intracellular bacteria or parasites and is increased in
patients with malignant tumour [56,57]. Patients with
chronic infection or cancer are predisposed to bone lossTa
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[1,58], and additional mechanisms may be involved that are
not mediated by IFN-γ.
As the kynurenine pathway is induced by inflammation, a
negative association with the kynurenine metabolites and
BMD could be expected. An unexpected finding was the
positive association of BMD with xanthurenic acid and
3-hydroxyanthranilic acid. However, 3-hydroxyanthranilic
acid has been found earlier to inhibit proinflammatory
cytokines and may down-regulate neuroinflammation [59].
Further, low 3-hydroxyanthranilic acid among osteoporotic
patients compared to controls was found in a study by
Forrest et al. [36], findings which are in concordance with
ours. Xanthurenic acid has been associated with cell
apoptosis and oxidative stress in experimental studies and
putatively related to ageing and disease development
[60,61]. We found, however, that xanthurenic acid was asso-
ciated positively with BMD in both age and sex groups, sug-
gesting a bone protective role for this metabolite. This
finding illustrates the complexity of the kynurenine
pathway, as metabolites may possess both pro- and anti-
inflammatory properties, possibly dependent upon the
organs or tissues involved.
Cortical bone loss is particularly rapid during the first
years after menopause in women, but gradually slows down
and becomes more similar to bone loss in men [62]. Experi-
mental evidence suggests that oestrogen withdrawal at
menopause leads to activation of T cells and thereby
increased release of IFN-γ [14]. We did not find any signifi-
cant associations between BMD and the inflammation
markers among women aged 46–49 years in our study, the
age during which postmenopausal-accelerated bone loss is
expected to begin. However, the cross-sectional design of
our study is not optimal to detect any such associations
related to bone loss induced by oestrogen deficiency.
In conclusion, the previously reported association
between inflammation and BMD [1] was confirmed for the
oldest subjects in this study. Associations between several of
the kynurenines and BMD indicate a role of the IFN-γ-
activated kynurenine pathway in bone metabolism. Our
study suggests that neopterin and KTR are independent risk
factors for low BMD, but it remains unclear as to whether
this is mediated directly by these metabolites, or whether
IFN-γ-mediated inflammation and bone degradation are
stimulated by a common causal factor through separate
mechanisms. Possible separate effects of tryptophan degra-
dation products on bone tissue should be investigated
further in experimental studies. Prospective studies are
required to assess whether altered levels of kynurenines
precede the onset of bone loss.
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Table 3. Associations between inflammatory markers/metabolites of the kynurenine pathway and bone mineral density in multiple linear regression
analysis,* the Hordaland Health Study (n = 5312).
46–49 years 71–74 years
Men (n = 1166–1229) Women (n = 1776–1862)† Men (n = 976–1017)† Women (n = 1161–1204)†
Beta‡ P-value Beta P-value Beta P-value Beta P-value
CRP (μg/ml) −0·02 0·39 0·00 0·92 −0·09 0·003 0·01 0·73
Neopterin (nmol/l) 0·01 0·67 −0·02 0·34 −0·13 <0·001 −0·06 0·019
KTR 0·00 0·88 −0·02 0·34 −0·12 <0·001 −0·09 0·001
Tryptophan (μmol/l) 0·03 0·29 0·03 0·19 0·11 <0·001 0·10 <0·001
Kynurenine (μmol/l) 0·02 0·60 0·00 0·98 −0·04 0·16 0·00 0·89
Kynurenic acid (nmol/l) 0·03 0·28 0·04 0·054 0·01 0·69 0·03 0·26
Anthranilic acid (nmol/l) 0·04 0·17 −0·03 0·15 −0·02 0·48 −0·01 0·80
3-Hydroxykynurenine (nmol/L) 0·03 0·22 −0·01 0·73 −0·03 0·38 −0·04 0·12
Xanthurenic acid (nmol/l) 0·07 0·013 0·08 <0·001 0·14 <0·001 0·12 <0·001
3-Hydroxyanthranilic acid (nmol/l) 0·03 0·35 0·06 0·010 0·05 0·11 0·07 0·005
*Adjustments were made for body mass index, cotinine and estimated glomerular filtration rate (over/below 60 ml/min). †Numbers vary accord-
ing to analysed metabolite. ‡Beta = estimated standardized regression coefficient; CRP = C-reactive protein; KTR = kynurenine/tryptophan ratio.
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